FDA May Allow Furberg To Participate In COX-2 Advisory Committee
This article was originally published in The Pink Sheet Daily
Executive Summary
No final decision has been made on the drug safety committee member's eligibility for the early 2005 meeting, FDA maintains. Acting Commissioner Crawford backs away from early statements that Furberg would not participate.
You may also be interested in...
FDA COX-2 Review Will Include Input From Furberg, Full Rx Safety Advisory Cmte.
After initially being asked not to appear at the meeting, Wake Forest's Furberg is formally re-invited to participate at the Feb 16-18 advisory committee meeting. FDA first invited only two members of the drug safety committee but has expanded its invitation to the full committee.
FDA COX-2 Review Will Include Input From Furberg, Full Rx Safety Advisory Cmte.
After initially being asked not to appear at the meeting, Wake Forest's Furberg is formally re-invited to participate at the Feb 16-18 advisory committee meeting. FDA first invited only two members of the drug safety committee but has expanded its invitation to the full committee.
Bextra Meta-Analyses Could Be Taken Up At February COX-2 Advisory Cmte.
Drug safety committee member Curt Furberg's meta-analysis suggests increased risk of cardiovascular events for patients with osteoarthritis and rheumatoid arthritis taking Bextra versus placebo while Pfizer points to a meta-analysis of 8,000 patients that did not show an effect. Furberg disinvited by FDA to participate in committee meeting following public comments.